Can Cardiovascular Disease (CVD), the world’s leading chronic killer, be predicted, cured and ultimately prevented? – A Discussion with Dr. Joe Tunac and Arterez
Dr. Josefino B. Tunac has identified the multi-factorial root causes of cardiovascular disease (CVD) and now proved they can be characterized, cured and ultimately prevented. Please join this important discussion with the Arterez team; Dr. Tunac, President & Chairman, Mr. Michael Brennan, Chief Executive Officer and Mr. Brett Homovec, Chief Financial Officer about an opportunity to support the team that is literally changing the rules for CVD that could save and improve millions of precious lives.
Cardiovascular Disease (CVD) is the world’s leading chronic killer impacting more than one-third of the world’s population. US direct and indirect healthcare costs due to CVD is expected to grow to an estimated $1.5 trillion by 2030. Among the top 150 developing nations worldwide, CVD is the leading health risk and cost.
Arterez, Inc. is a Michigan biosciences group led by Dr. J.B. Tunac that has discovered the upstream etiology of chronic vascular disease. The company has developed and tested 9 new chemical entities in 30+ combinations and has since developed its first fixed dose oral therapy, Embotricin™, that prevents formation of emboli (clots) via plaque regression and restoration of the endothelial glycocalyx, while also addressing inflammation and oxidation, enabling healing at the cellular level rather than targeting symptoms. The company has also developed a biomarker panel for treatment monitoring, known as GlycoCardia™ that can also be used as a diagnostic tool for disease identification, staging and classification. First in-human studies are expected to begin in 2023. More information available at www.Arterez.com.
source
